EXACT Sciences Reaches New 1-Year High at $19.15 (EXAS)
EXACT Sciences (NASDAQ:EXAS) shares reached a new 52-week high during trading on Tuesday , AR Network reports. The stock traded as high as $19.15 and last traded at $17.93, with a volume of 11,524,662 shares changing hands. The stock had previously closed at $17.09.
A number of analysts have recently weighed in on EXAS shares. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of EXACT Sciences in a research note on Tuesday. They now have a $20.00 price target on the stock, up previously from $19.00. Separately, analysts at Benchmark Co. upgraded shares of EXACT Sciences to a “buy” rating in a research note on Tuesday. Finally, analysts at Jefferies Group raised their price target on shares of EXACT Sciences from $18.00 to $20.00 in a research note on Wednesday, July 23rd. They now have a “buy” rating on the stock. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $19.50.
The stock’s 50-day moving average is $16.42 and its 200-day moving average is $14.19. The company’s market cap is $1.448 billion.
EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Tuesday, July 22nd. The company reported ($0.24) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.25) by $0.01. During the same quarter in the prior year, the company posted ($0.19) earnings per share. Analysts expect that EXACT Sciences will post $-1.14 EPS for the current fiscal year.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.
Receive News & Ratings for EXACT Sciences Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences Co and related companies with Analyst Ratings Network's FREE daily email newsletter.